graphic of an open envelope with a speech bubble containing an ellipsis near it

The Pharmaceutical Research and Manufacturers of America (PhRMA) is pleased to submit comments on the proposed rule published by the HHS Office of the Inspector General (OIG) concerning safe harbor protections under the Federal Anti-Kickback Statute (AKS) and exceptions to the Civil Monetary Penalty (CMP) law regarding beneficiary inducements for certain coordinated care, value-based, and patient engagement arrangements.

Download the full letter below.

graphic of an open envelope with a speech bubble containing an ellipsis near it

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.